Insights and Interventions in Acute Migraine Treatment

Jointly provided by Partners for Advancing Clinical Education (PACE) and Miller Medical Communications, LLC.

This activity is supported by an independent educational grant from Impel Pharmaceuticals, Inc.

Program Overview

Whereas the full spectrum of recent advances in the management of migraine is an important consideration for individuals who suffer from this condition, expanded treatment options are particularly important for acute migraine treatment because all migraine patients can benefit from them. This activity reviews new therapeutic options for acute migraine treatment, including new drug classes and novel delivery options for established drug classes.

Target Audience

This activity is intended for health care professionals engaged in the treatment of acute migraine.

Educational Objectives

Upon completion of this activity, participants should be able to:

• Identify gaps in the quality of acute care provided to patients with migraine, the impact on patient quality of life, and opportunities to improve outcomes
• Evaluate new migraine-specific therapies for acute migraine treatment for appropriate patients

Faculty

Nada Hindiyeh, MD, FAHS
Director, Headache Medicine
Metrodora Institute
West Valley City, Utah

Jennifer Robblee, MD, MSc, FRCPC
Assistant Professor of Neurology
Lewis Headache Center
Barrow Neurological Institute
Phoenix, Arizona
Assistant Professor of Neurology (Clinical)
Creighton University
Omaha, Nebraska
University of Arizona
Tucson, Arizona

Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Nada Hindiyeh, MD, FAHS
Consultant, Advisor, Speaker: Abbvie, Eli Lilly, Impel

Jennifer Robblee, MD, MSc, FRCPC
Consultant, Advisor, Speaker: Abbvie, Impel
Researcher: Abbvie, Barrow Neurological Foundation, Eli Lilly
Royalties or Patent Beneficiary: MedLink Neurology, NeuroDiem

Planners and Managers

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Miller Medical Communications, LLC, planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Miller Medical Communications, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)

Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS

Plug-in: Adobe® Flash® Player 10

• Adobe® Flash® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

Instructions for Credit

• There are no fees for participating in and receiving CME credit for this activity.
• During the period August 7, 2023, through August 7, 2024, participants must read the educational objectives and faculty disclosures and study the educational activity.
• If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation.
• Upon registering and successfully completing the post-test with 3 out of 4 correct or better and activity evaluation, your certificate will be made available immediately.

Release date: August 7, 2023
Expiration date: August 7, 2024
Estimated time to complete activity: 45 minutes

For additional information about the accreditation of this activity, please visit www.partnersed.com.